von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.
about
Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.Molecular approaches for improved clotting factors for hemophilia.Factor VIII therapy for hemophilia A: current and future issues.Novel therapeutic approaches for haemophilia.Longer-acting clotting factor concentrates for hemophilia.2017 Clinical trials update: Innovations in hemophilia therapy.Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.Personalized prophylaxis in people with hemophilia A: challenges and achievements.High-affinity von Willebrand factor binding does not affect the anatomical or hepatocellular distribution of factor VIII in rats.Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.Efficient stabilization of recombinant human coagulation factor VIII in the milk of transgenic mice using hFVIII and vWF co-expression vector transduction.Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.Serum-free suspension culturing of human cells: adaptation, growth, and cryopreservationProtein Therapeutic: Production, Application, and Future Scenario
P2860
Q34045763-FCE103F7-7485-4AEF-8352-3794981B07BDQ35612397-43018368-FADB-4934-96C9-5450DE8C9E1CQ37334700-99B4F057-B1A7-42F2-8091-A94AD61F12A0Q38203350-FE5C29DB-579B-4623-B189-2A3FDDF8CAF8Q38293116-41E72513-F6F7-412B-A2C1-80BE51BBC9D2Q38543283-B97B732E-9A4C-4794-B78A-1B95FF512655Q38937725-F0DC5C59-A36B-4E38-9977-16597540E9D3Q38944642-498E6E38-B336-41AA-837C-B3DA793FEE42Q38997467-7D7F6BBF-84C6-427C-9AD1-8DC4626B3D58Q39631688-28469D37-E5EE-4D2A-82E5-74F20C58F859Q41591597-F31BEA7A-6EAF-4C6C-A907-73FDDF113671Q42161184-824F36D9-0F0C-4796-B41D-51BE65EAD090Q44051815-ABB181D1-B7C0-44A7-AF5A-2A1ABF73ACB1Q56786995-5B34BFB3-408B-4413-BC47-767F189BBAA0Q57345827-2F56BE81-C98E-4C9E-8B85-FF40F61E95E8
P2860
von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.
@en
von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.
@nl
type
label
von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.
@en
von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.
@nl
prefLabel
von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.
@en
von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.
@nl
P2093
P2860
P356
P1433
P1476
von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.
@en
P2093
D Schneider
F Monteclaro
J E Murphy
R I Feldman
P2860
P304
P356
10.1111/HAE.12116
P577
2013-03-28T00:00:00Z